Clinicopathologic characteristics of patients with early-stage, gastric DLBCL with and without histologic evidence of MALT origin
| Frontline treatment . | Pure (de novo) DLBCL . | DLBCL(MALT) . | P* . | |
|---|---|---|---|---|
| Chemotherapy, n = 30 . | Antibiotics, n = 16 . | Antibiotics, n = 34 . | ||
| Clinicopathologic characteristics | ||||
| Median age, y (range) | 65 (20-87) | 63 (34-88) | 55 (35-83) | .283† |
| Sex, male/female | 16/14 | 6/10 | 12/22 | .312‡ |
| Stage | .022‡ | |||
| IE, n (%) | 19 (63.3) | 9 (56.3) | 30 (88.3) | |
| IIE1, n (%) | 11 (36.7) | 7 (43.8) | 4 (11.7) | |
| Endoscopic features, n (%) | .537§ | |||
| Gastritis-like or multiple erosion on infiltrative mucosa | 7 (23.3) | 3 (18.8) | 11 (32.4) | |
| Ulceration or ulcerated mass | 18 (60.0) | 11 (68.8) | 18 (52.9) | |
| Erosions on giant nodular folds | 3 (10.0) | 1 (6.3) | 3 (8.8) | |
| Mixed | 2 (6.7) | 1 (6.3) | 2 (5.9) | |
| Location of tumor(s), n (%) | .790§ | |||
| Antrum | 12 (40.6) | 6 (37.5) | 10 (29.4) | |
| Angularis | 1 (3.3) | 0 (0) | 3 (8.8) | |
| Middle body, lower body, or both | 7 (23.3) | 5 (31.3) | 8 (23.5) | |
| Upper body, fundus, or both | 3 (10.0) | 1 (6.3) | 3 (8.8) | |
| ≥ 2 components | 7 (23.3) | 4 (25.0) | 10 (29.4) | |
| Depth of gastric wall involvement, n (%)‖ | .831‡ | |||
| Submucosa or above | 9/22 (40.9) | 5/16 (31.2) | 10/27 (37.0) | |
| Muscularis propria or beyond | 13/22 (59.1) | 11/16 (68.8) | 17/27 (63.0) | |
| Initial pathologic features, n (%) | ||||
| DLBCL without MALT lymphoma | 30 (100) | 16 (100) | ||
| MALT lymphoma with foci of large-cell aggregations | 19 (55.9) | |||
| DLBCL with foci of CCL, LEL, or both | 15 (44.1) | |||
| Frontline treatment . | Pure (de novo) DLBCL . | DLBCL(MALT) . | P* . | |
|---|---|---|---|---|
| Chemotherapy, n = 30 . | Antibiotics, n = 16 . | Antibiotics, n = 34 . | ||
| Clinicopathologic characteristics | ||||
| Median age, y (range) | 65 (20-87) | 63 (34-88) | 55 (35-83) | .283† |
| Sex, male/female | 16/14 | 6/10 | 12/22 | .312‡ |
| Stage | .022‡ | |||
| IE, n (%) | 19 (63.3) | 9 (56.3) | 30 (88.3) | |
| IIE1, n (%) | 11 (36.7) | 7 (43.8) | 4 (11.7) | |
| Endoscopic features, n (%) | .537§ | |||
| Gastritis-like or multiple erosion on infiltrative mucosa | 7 (23.3) | 3 (18.8) | 11 (32.4) | |
| Ulceration or ulcerated mass | 18 (60.0) | 11 (68.8) | 18 (52.9) | |
| Erosions on giant nodular folds | 3 (10.0) | 1 (6.3) | 3 (8.8) | |
| Mixed | 2 (6.7) | 1 (6.3) | 2 (5.9) | |
| Location of tumor(s), n (%) | .790§ | |||
| Antrum | 12 (40.6) | 6 (37.5) | 10 (29.4) | |
| Angularis | 1 (3.3) | 0 (0) | 3 (8.8) | |
| Middle body, lower body, or both | 7 (23.3) | 5 (31.3) | 8 (23.5) | |
| Upper body, fundus, or both | 3 (10.0) | 1 (6.3) | 3 (8.8) | |
| ≥ 2 components | 7 (23.3) | 4 (25.0) | 10 (29.4) | |
| Depth of gastric wall involvement, n (%)‖ | .831‡ | |||
| Submucosa or above | 9/22 (40.9) | 5/16 (31.2) | 10/27 (37.0) | |
| Muscularis propria or beyond | 13/22 (59.1) | 11/16 (68.8) | 17/27 (63.0) | |
| Initial pathologic features, n (%) | ||||
| DLBCL without MALT lymphoma | 30 (100) | 16 (100) | ||
| MALT lymphoma with foci of large-cell aggregations | 19 (55.9) | |||
| DLBCL with foci of CCL, LEL, or both | 15 (44.1) | |||
LEL indicates lymphoepithelial lesions.
Comparison of discrete variables between pure (de novo) DLBCL and DLBCL(MALT).
P values (2-sided) were calculated using the Student t test.
P values (2-sided) were calculated using the Fisher exact test.
P values (2-sided) were calculated using 1-way ANOVA.
Gastric wall involvement was evaluated in 65 patients in total. Evaluation was by endoscopic ultrasonography in 64 patients and by histologic examination of surgical specimen in one gastric DLBCL(MALT) patient.